Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review - PubMed (original) (raw)
Review
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
H Maeda et al. J Control Release. 2000.
Abstract
Most solid tumors possess unique pathophysiological characteristics that are not observed in normal tissues or organs, such as extensive angiogenesis and hence hypervasculature, defective vascular architecture, impaired lymphatic drainage/recovery system, and greatly increased production of a number of permeability mediators. The phenomenon now known as the enhanced permeability and retention (EPR) effect for lipid and macromolecular agents has been observed to be universal in solid tumors. Primarily, enhanced vascular permeability will sustain an adequate supply of nutrients and oxygen for rapid tumor growth. The EPR effect also provides a great opportunity for more selective targeting of lipid- or polymer-conjugated anticancer drugs, such as SMANCS and PK-1, to the tumor. In the present review, the basic characteristics of the EPR effect, particularly the factors involved, are described, as well as its modulation for improving delivery of macromolecular drugs to the tumor. Tumor-specific vascular physiology is also described.
Similar articles
- Factors and mechanism of "EPR" effect and the enhanced antitumor effects of macromolecular drugs including SMANCS.
Fang J, Sawa T, Maeda H. Fang J, et al. Adv Exp Med Biol. 2003;519:29-49. doi: 10.1007/0-306-47932-X_2. Adv Exp Med Biol. 2003. PMID: 12675206 Review. - Exploiting the dynamics of the EPR effect and strategies to improve the therapeutic effects of nanomedicines by using EPR effect enhancers.
Fang J, Islam W, Maeda H. Fang J, et al. Adv Drug Deliv Rev. 2020;157:142-160. doi: 10.1016/j.addr.2020.06.005. Epub 2020 Jun 14. Adv Drug Deliv Rev. 2020. PMID: 32553783 Review. - Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines.
Greish K. Greish K. J Drug Target. 2007 Aug-Sep;15(7-8):457-64. doi: 10.1080/10611860701539584. J Drug Target. 2007. PMID: 17671892 Review. - Vascular permeability in cancer and infection as related to macromolecular drug delivery, with emphasis on the EPR effect for tumor-selective drug targeting.
Maeda H. Maeda H. Proc Jpn Acad Ser B Phys Biol Sci. 2012;88(3):53-71. doi: 10.2183/pjab.88.53. Proc Jpn Acad Ser B Phys Biol Sci. 2012. PMID: 22450535 Free PMC article. Review. - Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications.
Maeda H, Fang J, Inutsuka T, Kitamoto Y. Maeda H, et al. Int Immunopharmacol. 2003 Mar;3(3):319-28. doi: 10.1016/S1567-5769(02)00271-0. Int Immunopharmacol. 2003. PMID: 12639809 Review.
Cited by
- Assessing the biocompatibility and stability of CeO2 nanoparticle conjugates with azacrowns for use as radiopharmaceuticals.
Khabirova S, Menshikov-Tonyan M, Aleshin G, Prikhodko A, Kozlov D, Anokhin E, Babeshkin K, Titchenko N, Zubenko A, Shchukina A, Fedorov Y, Kalmykov S. Khabirova S, et al. RSC Med Chem. 2024 Sep 27. doi: 10.1039/d4md00515e. Online ahead of print. RSC Med Chem. 2024. PMID: 39345713 Free PMC article. - Hyaluronic Acid-Modified Micelles of Azithromycin and Quercetin Against Infections Caused by Methicillin-Resistant Staphylococcus Aureus.
Zhang Z, Chen M, Wang J, Liu M, Guo R, Zhang L, Kong L, Liu Y, Yu Y, Li X. Zhang Z, et al. Int J Nanomedicine. 2024 Sep 16;19:9637-9658. doi: 10.2147/IJN.S476471. eCollection 2024. Int J Nanomedicine. 2024. PMID: 39309186 Free PMC article. - Advancing Ovarian Cancer Therapeutics: The Role of Targeted Drug Delivery Systems.
Lin Q, Li J, Abudousalamu Z, Sun Y, Xue M, Yao L, Chen M. Lin Q, et al. Int J Nanomedicine. 2024 Sep 10;19:9351-9370. doi: 10.2147/IJN.S478313. eCollection 2024. Int J Nanomedicine. 2024. PMID: 39282574 Free PMC article. Review. - Theranostic Diagnostics.
Ali MU, Chaudhary BN, Panja S, Gendelman HE. Ali MU, et al. Results Probl Cell Differ. 2024;73:551-578. doi: 10.1007/978-3-031-62036-2_22. Results Probl Cell Differ. 2024. PMID: 39242393 Review. - Treatment options for tumor progression after initial immunotherapy in advanced non-small cell lung cancer: A real-world study.
Li Y, Zhao J, Li R, Yao X, Dong X, Zhang R, Li Y. Li Y, et al. Neoplasia. 2024 Sep 2;57:101043. doi: 10.1016/j.neo.2024.101043. Online ahead of print. Neoplasia. 2024. PMID: 39226660 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources